The core activity of Philochem is the development and research of bioactive compounds for cancer treatment, particularly in the areas of Target Discovery, Ligand Discovery and small molecule therapeutics. The company focuses on developing compounds that target the site of the disease while protecting healthy tissue. The company's products include various radiopharmaceuticals for imaging and therapy of cancer, such as 68Ga-OncoFAP, 177Lu-OncoFAP and 68Ga-OncoCAIX.
AI-generated
Offering
Products & services
Industry:Research & Development
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Ligand-based targeting, discovery and development of therapeutics based on small organic ligands, cyclic peptides and antibody fragments; validation in disease models and transfer to clinical trials.
DNA-Encoded Chemical Libraries (DELs)
DNA-encoded chemical libraries for discovery of small organic ligands, screening of binders against selected targets, and collaborations or fee-for-service projects.
Cyclic Peptide Phage Libraries
Cyclic peptide phage libraries for isolating target-specific cyclic peptides, used in internal discovery programs and in collaborations with industrial or academic partners.
Antibody Phage Libraries
Antibody phage libraries for isolating human monoclonal antibodies against antigens of interest, used in internal discovery programs and collaborative projects.
Partnering & Fee-For-Services
Collaborations on proprietary small-molecule ligands, DNA-encoded chemical libraries, antibodies and cyclic peptides, including screening projects and licensing agreements.
Small Molecule Therapeutics
Small-molecule therapeutics for tumour targeting, including delivery of radionuclides, cytotoxic agents, immunomodulators and adaptors for universal CAR-T therapy.
Antibody-based Therapeutics
Antibody-cytokine fusion proteins and other antibody-based therapeutics for cancer, with applications also mentioned for inflammatory conditions.
Target identification and chemical proteomics
Discovery and validation of pharmaceutical targets, chemical proteomics, target identification, mass spectrometry-based biodistribution and MHC-I immunopeptidomics.
OncoFAP programmes
OncoFAP-based imaging and therapy programmes for various solid tumours, including 68Ga-, 18F- and 177Lu-based agents and OncoFAP-GlyPro-MMAE.
OncoACP3 programmes
OncoACP3 imaging and therapy programmes for prostate cancer, including 68Ga-, 18F-, 177Lu- and 225Ac-labelled candidates.
OncoCAIX programmes
OncoCAIX imaging and therapy programmes for renal cell carcinoma, including 68Ga-OncoCAIX and 177Lu-OncoCAIX.
Comparisons
Philochem AG in comparison
Soon
Industry comparisons are coming soon
We're preparing industry comparisons that rank Philochem AG by reviews, experience and specialisations.
Knowledge
No knowledge articles yet
Once Philochem AG has claimed this profile, we'll publish editorial articles and case studies here together.